Research Project
Grant-in-Aid for Young Scientists (B)
In this study, we demonstrated the effect and safety of rituximab for various refractory immune-mediated neuropathies. Rituximab (375 mg/m^2 intravenously each week for 4 weeks) was administered in an openlabel design to one patient with multifocal motor neuropathy (MMN), one with chronic inflammatory demyelinating polyneuropathy (CIDP), one with neuropathy associated with Sjogren's syndrome (SN), and four with anti-MAG IgM-MGUS neuropathy (IgM-N). Reduction of total IVIg requirements of a patient with MMN, although the effect was only temporary, were suggested to be responded to rituximab. Improvement of clinical status in three patients with IgM-N suggeted that rituximab was well tolerated and is a promising new drug. No adverse events occurred in all patients.
All 2011 2010 2009
All Journal Article (22 results) (of which Peer Reviewed: 18 results) Presentation (31 results) Book (1 results)
Annual Review神経
Pages: 300-309
Annual Review神経2011
Volume: 2011 Pages: 300-309
J Neuropathol Exp Neurol. 69
Pages: 1143-1157
J Neurol Neurosurg Psychiatry. (Epub ahead of print)
Brain. 133
Pages: 2881-2896
10025625514
Muscle Nerve. 42
Pages: 433-435
J Clin Neurosci. 17
Pages: 1003-1008
J Neurol Neurosurg Psychiatry. 81
Pages: 586-587
Pages: 583-585
神経内科 72
Pages: 275-283
J Neuropathol Exp Neurol.
Volume: 69 Pages: 1143-1157
J Neurol Neurosurg Psychiatry
Volume: (Epub ahead of print)
Brain.
Volume: 133 Pages: 2881-2896
Muscle Nerve.
Volume: 42 Pages: 433-435
J Clin Neurosci.
Volume: 17 Pages: 1003-1008
Volume: 81 Pages: 586-587
J Neurol Neurosurg Psychiatry.
Volume: 81 Pages: 583-585
神経内科
Volume: 72 Pages: 275-283
Neurology 73
Pages: 1348-1352
J Neurol Sci. 287
Pages: 178-184
Amyloid (Epub ahead of print)
J Neurol Sci. 279
Pages: 57-61
10025625884